Please assess the completion status of the following clinical trial:

Trial Title: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have completed the double-blind phase of Study TKT024, defined as completing the Week 53 final evaluations.~* Patient, patient's parent(s), or legally authorized representative must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~* Patient has received treatment with an investigational therapy other than iduronate-2-sulfatase in Study TKT024 within the past 60 days.~* Patient is unable to comply with the protocol (e.g., due to a medical condition such as cervical cord compression or uncooperative attitude) or is unlikely to complete the study, as determined by the investigator.~* Patient has experienced an adverse reaction to study drug in Study TKT024, which contraindicates further treatment with idursulfase.~* Patient with known hypersensitivity to any of the components of idursulfase.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idursulfase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).